Title: 213Bi-radioimmunotherapy Defeats Early-stage Disseminated Gastric Cancer in Nude Mice
Authors: BECK R.SEIDL C.PFOST B.MORGENSTERN ALFREDBRUCHERTSEIFER FRANKBAUM M.SCHWAIGER M.SENEKOWITSCH-SCHMIDTKE R.
Citation: CANCER SCIENCE vol. 98 no. 8 p. 1215-1222
Publisher: BLACKWELL PUBLISHING
Publication Year: 2007
JRC N°: JRC41950
ISSN: 1347-9032
URI: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1349-7006.2007.00525.x?prevSearch=allfield%3A%28morgenstern%29
http://publications.jrc.ec.europa.eu/repository/handle/JRC41950
DOI: 10.1111/j.1349-7006.2007.00525.x
Type: Articles in Journals
Abstract: The a-emitter 213Bi is characterized by a high relative biological effectiveness. 213Bi-immunoconjugates targeting tumor-specific d9-E-cadherin have been proven to effectively kill tumor cells in a murine peritoneal carcinomatosis model. The aim of the present study was to optimize the efficacy of 213Bi-radioimmunotherapy for disseminated gastric cancer in a mouse model of early- and advanced-stage disease and to evaluate the long-term toxicity of 213Bi-immunoconjugates. For that purpose, nude mice were treated with different activities of 213Bi-d9 monoclonal antibody (MAb) targeting d9-E-cadherin or unspecific 213Bi-d8MAb at days 1 or 8 after inoculation of HSC45-M2 gastric cancer cells expressing mutant d9-E-cadherin. Therapeutic efficacy was evaluated by monitoring survival for up to 300 days. Long-term toxicity was evaluated by the survival of tumor-free mice injected with 213Bi-immunoconjugates, kidney function parameters and histopathological examination of kidneys. We showed that survival was significantly prolonged following treatment of mice with 213Bi-immunoconjugates (0.37¿22.2 MBq) at day 1 after tumor cell inoculation (P < 0.002). Therapy with 1.85 MBq of 213Bi-d9MAb was most successful, defeating early-stage disease in 87% of all cases. Treatment at day 8 after tumor cell inoculation was less efficient. Long-term nephrotoxicity could only be observed following application of 22.2 MBq of 213Bi-d9MAb, the highest activity applied in the therapy trials. As treatment with 1.85 MBq 213Bi-d9MAb showed excellent therapeutic efficacy without any signs of acute or chronic toxicity, radioimmunotherapy with the a-emitter 213Bi is a promising concept for treatment of early peritoneal carcinomatosis. (Cancer Sci 2007; 98: 1215¿1222)
JRC Institute:Institute for Transuranium Elements

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.